Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olesoxime add-on to riluzole in amyotrophic lateral sclerosis
2008-007320-25Phase 2Completed
- Sponsor
- Trophos
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Olesoxime + riluzole with Placebo + riluzole (2 arms). Primary endpoint: Overall 18-month survival rate. Started Feb 2009; status: completed.
02
Drugs
olesoxime
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2008-007320-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007320-25.